

ACUTE MEDICAL TREATMENT OF  
BEHAVIOURAL CRISIS

# Rapid Tranquillisation Policy

The **primary** objective in the use of these guidelines is to bring to an end a period of highly disturbed behaviour in a patient resistive to intervention as **quickly** and as **safely** as possible

Key Words:	Rapid tranquillisation, aggression, behavioural disturbance
Version:	2
Adopted by:	Trust Policy Committee
Date this version was adopted:	18 February 2020
Name of Author:	Anthony Oxley
Name of responsible committee:	Medicines Management Group
Date issued for publication:	February 2020
Review date:	December 2021
Expiry date:	1 July 2022
Target audience:	All medical staff and qualified nursing staff who work in in-patient areas and day hospitals
Type of Policy	Clinical
Which relevant CQC Fundamental Standards?	12

## CONTRIBUTION LIST

### Key individuals involved in developing the document

Name	Designation
Anthony Oxley	Head of Pharmacy
Robyn McAskill	Pharmacy Clinical Services Manager
Zeibun Patel	Lead Pharmacist - MH&LD Prescribing Group
Rachel Calton	Lead Pharmacist - Education & Training
Jonathan Dexter	Advanced Nurse Practitioner, CHS
Dr R Wong	Consultant in care for the Elderly
Michelle Churcharad	Head of Nursing AMH/LD services
Rachael Shaw	Lead for Positive and Safe Seclusion
Dr T Hanley	Associate Specialist in Eating Disorders

### Circulated to the following individuals for comments

Name	Designation
Medicines Management Committee	
Quality Forum	
Positive and Safe Seclusion Group	

# Contents

Contents.....	3
Version Control and Summary of Changes.....	4
Equality Statement .....	5
Due Regard .....	5
Definitions that apply to this policy.....	6
THE POLICY.....	7
1.0 Summary of the Policy .....	7
2.0 Introduction .....	7
3.0 Purpose .....	7
4.0 Legal .....	8
5.0 Duties within the Organisation .....	9
6.0 Training .....	9
7.0 Initial Measures .....	10
8.0 Drugs for Rapid tranquillisation.....	11
9.0 Adults .....	12
10.0 Older and Frail Adults .....	15
11.0 After Rapid Tranquillisation.....	16
12.0 Patients with Eating Disorders.....	17
13.0 Documentation .....	18
14.0 Guidelines for Rapid Control Of Acutely Disturbed Younger Patients.....	19
15.0 Monitoring Compliance and Effectiveness.....	20
16.0 Links to Standards/Performance Indicators .....	20
17.0 Distribution and Implementation .....	21
APPENDICES.....	21
Appendix 1: Recording Sheet for IM Rapid Tranquillisation.....	21
Appendix 2: Quick Reference Guide to Rapid Tranquillisation (QRG) .....	24
Appendix 3: Due Regard.....	25
Appendix 4: Policy Training Requirements .....	27
Appendix 5: The NHS Constitution.....	28
Appendix 6: Privacy Impact Assessment Screening.....	29

## Version Control and Summary of Changes

Version number	Date	Comments (description change and amendments)
1.1	June 2012	Harmonisation of previous documents and update onto new proforma.
1.2	September 2012	Amendments incorporated following comments received by Policy Group in august 2012.
1.3	November 2012	Replacement of olanzapine IM with aripiprazole IM due to unavailability of olanzapine IM.
1.4	March 2013	Replacement of diazepam IV with lorazepam IV. Amendments incorporated to NHSLA Monitoring Section.
1.5	March 2014	Amendments to monitoring section.
1.6	September 2017	Harmonisation of previous documents and update onto new proforma. Inclusion of ECG statement. Update of tools used for recording of monitoring within the Trust.
1.7	July 2018	Review of policy with reference to NICE TA which recommends the use of promethazine with haloperidol following recommendation from CQC to consider this addition.
1.8	November 2019	Review of RT monitoring sheet and update. Highlighting drugs and doses so they are more prominent. Incorporation of CAMHS RT policy into the document. Addition of a paragraph for patients with Eating Disorders and their particular concerns.

**All LPT Policies can be provided in large print or Braille formats, if requested, and an interpreting service is available to individuals of different nationalities who require them.**

Did you print this document yourself?

Please be advised that the Trust discourages the retention of hard copies of policies and can only guarantee that the policy on the Trust website is the most up-to-date version.

**For further information contact:**

**Head of Pharmacy  
Pharmacy Department**

## Equality Statement

Leicestershire Partnership NHS Trust (LPT) aims to design and implement policy documents that meet the diverse needs of our service, population and workforce, ensuring that none are placed at a disadvantage over others.

It takes into account the provisions of the Equality Act 2010 and promotes equal opportunities for all.

This document has been assessed to ensure that no one receives less favourable treatment on the protected characteristics of their age, disability, sex (gender), gender reassignment, sexual orientation, marriage and civil partnership, race, religion or belief, pregnancy and maternity.

In carrying out its functions, LPT must have due regard to the different needs of different protected equality groups in their area.

This applies to all the activities for which LPT is responsible, including policy development and review.

## Due Regard

LPT must have **due regard** to the aims of eliminating discrimination and promoting equality when policies are being developed. Information about due regard can be found on the equality page on e-source and/or by contacting the LPT Equalities Team.

The due regard assessment template is Appendix 3 of this document

## Definitions that apply to this policy

<b>Rapid tranquillisation</b>	The use of injectable medication to control severe mental and behavioural disturbance, including aggression associated with mental illness
<b>Psychoactive substance</b>	A chemical substance that affects the processes of the mind
<b>PRN dose</b>	Medication prescribed for use on an “as required” basis
<b>Stat dose</b>	Medication prescribed as a one off dose.
<b>Neuroleptic naive</b>	Person who has not previously been treated with an antipsychotic (neuroleptic).
<b>Dystonia</b>	A neurological movement disorder, presenting as sustained muscle contractions, twisting and repetitive movements or abnormal postures.
<b>Extrapyramidal side effects (EPSE)</b>	A group of symptoms that can occur in persons taking antipsychotic medications e.g. tremor, akathisia, slurred speech, dystonia, bradykinesia, muscular rigidity
<b>Due Regard</b>	<p>Having due regard for advancing equality involves:</p> <ul style="list-style-type: none"> <li>• Removing or minimising disadvantages suffered by people due to their protected characteristics.</li> <li>• Taking steps to meet the needs of people from protected groups where these are different from the needs of other people.</li> <li>• Encouraging people from protected groups to participate in public life or in other activities where their participation is disproportionately low.</li> </ul>
<b>NEWS</b>	National Early Warning Scoring Tool
<b>EPMA</b>	Electronic Prescribing and Administration service
<b>NerveCentre</b>	System for electronic recording of patient observations.

# **THE POLICY**

## **1.0 Summary of the Policy**

Set of guidelines to assist medical staff in dealing with inpatients requiring intervention to control severe mental and behavioural disturbance.

## **2.0 Introduction**

Rapid tranquillisation (RT) is the administration of carefully monitored amounts of tranquillising drugs over brief intervals of time, to achieve rapid, short-term behavioural control of extreme agitation, aggression and potentially violent behaviour that places individuals or those around them at risk of physical harm or cause damage to property.

The aim of RT is to calm the person, and reduce the risk of violence and harm, rather than to treat the underlying psychiatric condition.

An optimal response would be a reduction in agitation or aggression without sedation, allowing the patient to participate in further assessment and treatment.

## **3.0 Purpose**

Aggressive disturbed behaviour can occur as a consequence of mental disorder, most frequently as the result of a series of complex interactions between a mentally ill person's inner world and their surroundings.

Often, extreme agitation, aggression and potentially violent behaviour can be calmed down by de-escalation techniques deployed by skilled and trained staff. However there are occasions when these methods fail and patients who cannot control their violent impulses need to be calmed down rapidly in order to ensure safety for all.

RT should be used only for calming a patient who is highly aroused, agitated, overactive, aggressive or making serious threats or gestures towards others or is being destructive to their surroundings, when other therapeutic interventions have failed to contain the behaviour.

Staff who use RT should be trained in the assessment and management of patients specifically in this context; this should include assessing and managing the risks of drugs (benzodiazepines and antipsychotics), using and maintaining the techniques and equipment needed for cardiopulmonary resuscitation, prescribing within therapeutic limits and using flumazenil (benzodiazepine antagonist).

On admission, staff should discuss with patients and, where appropriate, their carers, what may happen if they become disturbed or violent and provide them with the opportunity to express their needs and wishes in the likelihood of such an event.

Interpretation services are available for patients if required.

Nurses should administer medication only according to written prescriptions. Instruction by telephone (verbal orders) to administer a drug that has not been prescribed previously is not acceptable (Guidelines for the administration of medicines, Nursing and Midwifery Council 2004).

In managing disturbed behaviour, it is essential that nursing and medical staff should present a united and easy to understand format to the patient.

If there is disagreement among staff about whether or not to use RT, more senior staff i.e. line managers / senior medical staff must be consulted to clarify the management plan as quickly as possible.

## 4.0 Legal

Staff involved in RT should be mindful of and take account of the:

- relevant sections of the Mental Health Act 1983 and its Code of Practice
- the principles underlying the common law doctrine of 'necessity', and the requirements of the relevant articles of the European Convention on Human Rights, including Article 2 (right to life)
- Article 3 (the right to be free from torture or inhuman or degrading treatment or punishment)
- Article 5 (the right to liberty and security of person save in prescribed cases)

and

- Article 8 (the right to respect for private and family life), and the principle of 'proportionality'
- the Health and Safety at Work Act 1974, which place duties on both employers and employees, and applies to the risk of violence from patients and the public
- the Management of Health and Safety at Work Regulations 1992, which place specific duties on the employer to ensure suitable arrangements for the effective planning, organisation, control, maintenance and review of health and safety (these duties include ensuring that the risk assessments are undertaken and implemented).

It is also important to ensure that any developing situation or positive intervention takes into account the individual needs of patients related to:

- sensory impairment
- black and minority ethnic patients.
- patients with a physical impairment
- patients with a cognitive impairment
- gender assignment e.g. (are some members of staff who are restraining of the same sex)
- patients with communication difficulties.

- Frail older patients

## 5.0 Duties within the Organisation

### Prescriber

- To ensure patient's prescription includes details of what medication to use for RT, in what dose range, and with what frequency
- Minimum time between doses and the maximum dose to be administered in a specified period must be stated
- Consider medication already prescribed
- To complete the Rapid Tranquillisation Recording Sheet - Appendix 1

### Nurse in charge (of unit at time of RT)

To ensure:

- the RT is indicated, having exhausted other strategies to calm the patient
- the prescription is followed
- the patient has the appropriate physical observations completed
- written records are maintained - use NerveCentre
- to complete the Review of Rapid Tranquillisation - **Appendix 1**

### Pharmacists

to ensure prescriptions are checked for potential adverse interactions

### Clinicians

To:

- ensure the prescription for oral medication is followed
- undertake appropriate physical observations
- maintain written records - NerveCentre

## 6.0 Training

There is a need for training identified within this policy. In accordance with the classification of training outlined in the Trust Learning and Development Strategy, this training has been identified as Role Essential Training.

It is delivered via eLearning at least every 3 years. A record of the event will be recorded on uLearn.

Compliance is monitored in accordance with the Trust's Mandatory Training Policy. The governance group responsible for monitoring the training is the Medicines Management

Committee.

## 7.0 Initial Measures

### 7.1 Safety

The first step is to ensure safety of the patient, staff and others on the ward. This may involve:

- Making sure that enough staff members are available
- Considering the patient's preferences
- Considering past history of adverse reactions to medication
- Considering what worked in the past
- Physical restraint
- Removing the patient to a low stimulus environment
- Ensuring availability and easy accessibility of resuscitation equipment. e.g. pulse oximeter and drugs, including flumazenil

### 7.2 Assessment

Assess the situation within the multidisciplinary team.

Consider the likely diagnoses, physical illnesses, general physical state

e.g:

- pregnancy
- exhaustion
- dehydration
- recent test results

and current psychiatric and non-psychiatric medication, and alcohol and substance misuse.

A basic physical examination should be done. If this is not possible at the time, the reason should be documented and the physical examination done as soon as possible afterwards.

Use caution in patients who are already sedated or using alcohol or illicit drugs. Consider the patient's regular oral and depot medication, as they affect the dose requirements and side effects of the RT medication.

### 7.3 Pregnant Patients

**Special Care** must be taken when administering RT to a female patient during **any stage** of pregnancy. Additional medical advice may be required due to the possible additional complications that may arise. This situation may well require quite complex discussions with relatives / carers.

## 7.4 Elderly and Frail patients

In elderly patients consider:

- Dementia
- physical frailty
- delirium

Look for causes of confusion.

## 7.5 Non-pharmacological measures

Always use behavioural approaches and de-escalation techniques, e.g. talking down, distraction, time out etc. Even when they do not prevent the need for RT, they will help preserve the therapeutic relationship and improve safety.

Before administering any medication, inform the patient that medication needs to be given and that they will have the opportunity to take the medication orally.

## 8.0 Drugs for Rapid tranquillisation

### Try ORAL therapy

If refused, or the behavioural crisis escalates, begin to follow these guidelines when you have established:

- How to quickly contact a consultant / senior colleague
- The availability of mechanical ventilation / cardiac resuscitation equipment

**ALWAYS** discuss with a consultant / senior colleague if there is **ANYTHING** you are unhappy or uncertain about.

Remember that there is on-call pharmacist support at all times.

**After RT**, monitor:

- side effects
- the service user's pulse
- blood pressure
- respiratory rate
- temperature
- level of hydration
- and level of consciousness

at least every hour until there are no further concerns about their physical health status.

Monitor these every 15 minutes if the BNF maximum dose has been exceeded or the service user:

- appears to be asleep or sedated
- has taken illicit drugs or alcohol

- has a pre-existing physical health problem
  - has experienced any harm as a result of any restrictive intervention
- Planned recording of vital signs may be compromised by the clinical state of the patient.

The recording of these signs should be in the **Trust approved monitoring tool: NerveCentre**.

If monitoring is not possible, enter:

- Date
- Time
- “patient uncooperative to monitoring”

onto the Trust approved monitoring tool; NerveCentre

Refer to any advance directives that explain the patient’s preference for medication, if clinically appropriate.

RT is used to reduce markedly aggressive or over-aroused behaviour and agitation, rather than to sedate the individual. However, if the patient’s behaviour is very disturbed, it may become necessary to sedate a patient for safety reasons.

Antipsychotic drugs are used in RT for their calming and sedative effects. Their antipsychotic effect usually takes two weeks.

Benzodiazepines reduce arousal and cause sedation at higher doses. They have no antipsychotic effects.

Oral and IM prescriptions should be prescribed separately on EPMA chart.

IV and IM doses generally have 2 - 5 times higher potency than oral doses.

The ward team need to be clear about the level of nursing observations required and plan staffing accordingly.

## 9.0 Adults

### Lorazepam / Haloperidol and/or Promethazine

Administer **Lorazepam 1 - 2 mg IM**

OR

the combination of **Haloperidol 5 mg IM** with or without **Promethazine 50 mg IM**

All IM injections should be administered separately not mixed.

**Use Lorazepam monotherapy if:**

- There is little information available to guide choice of agents
- There is a history of cardiovascular disease
- An ECG shows prolonged QTc interval
- Or if there is no ECG

**Please note that the SPC for Haloperidol requires a CURRENT ECG prior to treatment with this drug.**

- Dose adjustments should be considered for younger and older patients or those with special requirements (see 10.0)
- If there is a partial response to **Haloperidol** that has been administered, consider a further dose after 1 hour up to a maximum dose of:  
  
20 mg/24hours.
- If Promethazine has been used in conjunction with haloperidol this may also be repeated after 1 - 2 hours up to a maximum of:  
  
100 mg/24 hours.
- If there is a partial response to **Lorazepam** that has been administered, consider a further dose after 2 hours up to a maximum of:  
  
4 mg/24 hours.
- If there has been no response to the medication that has been administered, use the alternate regime (i.e. Lorazepam or haloperidol depending on which was used first) unless contraindicated.

## **Aripiprazole**

If alternate regimes are contraindicated, consider IM Aripiprazole:

standard dose	mg	ml
healthy working age adults	9.75	1.3
elderly adults	5.25	0.7

With a 24 hour maximum dosage, via all routes, of

- 30 mg

A maximum of 3 injections can be given within a 24 hour period.

Following administration of IM injection, a further injection can be given 2 hours later if there is no response.

Aripiprazole IM may be used in combination with Lorazepam IM if clinically appropriate.

See Quick Reference Guide (QRG) to RT - Appendix 2

### **Notes:**

Consider giving IM or IV Procyclidine prophylactically with Haloperidol, but remember that this may cause or worsen any confusion present.

## 9.1 If there **IS** a response to RT medication administered

There is a high likelihood of recurrence of the crisis, unless treatment is instituted for the underlying disorder causing the behavioural emergency.

Therefore consider the following:

- Commence / re-commence oral antipsychotics.
- Give Zuclopentixol acetate (Clopixol Acuphase)

50 - 150 mg IM

to minimize likelihood of repeat injections.

- Clopixol Acuphase should **NOT** be used for RT.

It should only be considered if a patient responds to other short acting parenteral antipsychotics and it is anticipated that they will require further frequent doses of IM typical antipsychotics.

It is best reserved for people who have had a previous good response to Acuphase. It should not be given to:

- antipsychotic naïve patients
  - elderly patients
  - physically struggling patients.
- Clopixol Acuphase should be given only after assessing the response to previously injected drugs:
    - i.e. 30 - 60 minutes after IM injections:
      - Give 50 -150 mg IM and reassess after 24 hours
      - Give up to a maximum of 400 mg in 3 days
  - Assess patient for dystonia and other extrapyramidal side effects. Continue to monitor vital signs as above. Pulse oximeter should be available and should be used where appropriate.

Acute reversal of benzodiazepine induced unconsciousness requires the use of **Flumazenil**:

The initial dose is:

- 200 micrograms IV over 15 seconds.

A further dose of

- 100 micrograms

Can be given after 60 seconds where necessary

and repeated up to a total dose of 1 mg.

**Flumazenil must be administered by a Doctor or suitably qualified person.**

**If no doctor is available and there is concern for the patient's safety: please call the crash team on 2222, or where this is not available, call 9999.**

## 9.2 If there is **NO** response to RT medication administered

If there is a **partial response** to the medication that has been administered, consider a further dose.

If there has been **no response** to the medication that has been administered, use the alternate regime, (Lorazepam or haloperidol depending on which was used first), unless contraindicated.

Other medications may occasionally be used if a response from the above cannot be obtained, but only following discussion with a consultant psychiatrist.

## 10.0 Older and Frail Adults

### When the patient refuses oral medication

**Lorazepam            0.5 - 2.0 mg IM**

**OR**

The combination of

**Haloperidol            2.5 mg IM**

with or without

**Promethazine        25.0 mg IM**

**Please note that the SPC for Haloperidol requires a CURRENT ECG prior to treatment with this drug.**

If there is a **partial response** to **HALOPERIDOL** that has been administered, consider a further dose after 2 hours up to a maximum dose of:

- 5 mg/24 hours

If **PROMETHAZINE** has been used in conjunction with haloperidol this may also be repeated after 1-2 hours up to a maximum of

- 50 mg/24 hours

If there is a **partial response** to **LORAZEPAM** that has been administered, consider a further dose after 2 hours up to a maximum of:

- 2 mg/24 hours.

**If the diagnosis is uncertain or if haloperidol is not indicated**  
(i.e. there is evidence of **Parkinson's disease** and/or **Lewy Body Dementia**)

**give:**

**Aripiprazole 5.25 mg (0.7 ml) IM**

- Give a maximum of 15 mg of Aripiprazole IM in 24 hours.
- Consider giving IV or IM Procyclidine prophylactically with Haloperidol, but remember that this may cause or worsen any confusion present.
- If patient presents with Delirium, seek medical advice.
- Clopixol Acuphase is NOT recommended for older people

See Quick Reference Guide (QRG) to rapid tranquillisation - Appendix 2

## **11.0 After Rapid Tranquillisation**

After Rapid Tranquillisation, monitor:

- side effects
- the service user's pulse,
- blood pressure,
- respiratory rate,
- temperature,
- level of hydration
- and level of consciousness

at least every hour until there are no further concerns about their physical health status.

Monitor these every 15 minutes if the BNF maximum dose has been exceeded or the service user:

- appears to be asleep or sedated
- has taken illicit drugs or alcohol
- has a pre-existing physical health problem
- has experienced any harm as a result of any restrictive intervention

If the patient is asleep or unconscious, it is important to continue monitoring. In addition, monitor oxygen saturation by pulse oximeter. In case of a patient who is unconscious 1:1 observation by competent staff is required.

Consider a fluid chart if their fluid intake is poor, or if the patient appears dehydrated consider a medical review.

Staff will need to check the patients' colour and responsiveness at regular intervals, as both these areas could indicate that the patients' physical health is deteriorating as per section 7

## 12.0 Patients with Eating Disorders

Anorexia nervosa involves starvation and intense weight loss which not only denies the body of essential nutrients but forces the body to physiologically slow down to conserve energy.

In the early stages of treatment when patients are acutely starved and low in weight, cardiovascular symptoms and objective measures of cardiac impairment are not unusual. Patients can exhibit abnormally slow heart rate (bradycardia) and low blood pressure (the latter often the result of a combination of bradycardia, poor muscle bulk, electrolyte disturbance (impairing contractility) and dehydration.

These factors can individually or in combination contribute to an increased risk of heart failure.

Electrolyte disturbance commonly related to purging behaviours, including self-induced vomiting and laxative misuse can increase the hearts irritability and proneness to arrhythmia.

The literature contains several cases of anorexia nervosa with prolonged QTc interval although it is not clear what risk this presents to patients as a consequence. It is also worth considering issues connected to re-feeding syndrome in particular the possibility of low serum phosphate which can contribute to cardiac failure through reduced muscle contractility.

Incidentally, mitral valve prolapse due to poor muscle bulk (reversible on weight restoration) and pericardial effusion can also be detected more often with echocardiogram than through clinical examination. These last two findings do not necessarily present with clinical symptoms or significant impairment. Clearly consideration needs to be given to medications prescribed in this patient group that may have prolonged QTc interval.

Psychiatric comorbidity is common in patients with anorexia nervosa and thus by extension, so is psychotropic prescribing.

Taking all of this into consideration it seems prudent to consider this group of patients as frail and having a heightened risk of adverse consequences from medications prescribed acutely in the context of RT. A sensible approach might be to start with lower doses and titrate further doses in response to clinical need and close reassessment of the patient especially cardiovascular status.

## 13.0 Documentation

Documentation would include:

- Completion of an incident form as per the Incident Reporting Policy
- The legal basis of administering RT on the recording sheet. (e.g. Indication, capacity to consent, consented or not)
- Doses of drug/s used. (Whether above BNF or NICE recommended doses)
- Use of de-escalating techniques on the recording sheet
- Physical parameters as above on NerveCentre
- Reasons why observations could not be performed (if applicable) on NerveCentre
- Reasons for use of alternative medications in the case records

If staff are unable to take observations due to mental state of the patient and risk to staff, this should be clearly noted in the current progress notes (electronic or paper).

### Other interventions

Provide explanation, advice, reassurance and support to the patient, their carers and any other persons who may have witnessed the incident.


Transfer the patient for nursing in a Low Stimulus Environment or side room.

Whenever possible establish the patient on regular medication with clear instructions regarding regular review.

If in any doubt, a senior member of staff should be consulted. For doctors this means the Consultant, or the senior doctor on call. For nurses this means the duty manager.

# 14.0 Guidelines for Rapid Control Of Acutely Disturbed Younger Patients

Aged 12-18 years - in inpatient setting



## 15.0 Monitoring Compliance and Effectiveness

The requirements of this policy with regard to training of staff, will be audited at least biannually.

The requirements of this policy with regard to medicines administered, and monitoring of service users after rapid tranquillisation, will be audited through an ongoing programme of ward level monitoring overseen by the Medicines Management Committee. This requirement will be incorporated into the Trust's clinical audit plan.

Ref	Minimum Requirements	Evidence for Self-assessment	Process for Monitoring	Responsible Individual / Group	Frequency of monitoring
	Training	ESR employee records	Check on ESR if training completed within the time frame required.	Managers	Every 3 years
	Medicines administered	EPMA records	Audit biannually	Medicines Management Committee / Medicines Audit Group	Ongoing monitoring
	Monitoring of service users after rapid tranquillisation	Patient records	Audit	Medicines Management Committee / Medicines Audit Group	Ongoing monitoring

## 16.0 Links to Standards/Performance Indicators

A description of how the procedural document links to Care Quality Commission (CQC) Regulations (e.g. Regulation number and domain) or other standards/performance indicators should be included (e.g. NHS Improvement notices, NICE guidance).

Target/standards	Activity	Key performance indicator
<p>Regulation 12 - <b>Safe Care and Treatment</b>  <b>12(1)</b> Providers should consult nationally recognised guidance about delivering safe care and treatment and implement this as appropriate.</p>	<p>When short acting IM medication* is administered to patients to control severe mental and behavioural disturbance, including aggression associated with mental illness</p>	<p>Short acting IM medication* is administered to patients in accordance with this policy, which was developed with reference to NICE NG10 and QS154</p> <p>Evidenced by Version Control, page 4 and References, page 20</p>
		<p>Short acting IM medication* is administered to patients in accordance with the Mental Health Act 1983.</p> <p>Evidenced by Section papers, form 62 or T3 documentation in patients notes.</p>
<p>Regulation 12 - <b>Safe Care and Treatment</b>  <b>12(2)(b)</b> doing all that is reasonably practicable to mitigate any such risks; The provider must have arrangements to take appropriate action if there is a clinical or medical emergency</p>	<p>*Lorazepam, Promethazine, Haloperidol, or Aripiprazole.</p>	<p>Short acting IM medication* is administered to patients in a ward environment that has suitable resuscitation equipment.</p> <p>Evidenced by checking which ward patient was on at time of administration and cross referencing this with resuscitation equipment checks.</p>

## 17.0 Distribution and Implementation

This document will be widely circulated within the Trust including all Directors, Senior Managers and Policy Leads and will be made available on the Trust's Intranet and Internet sites. Relevant changes will be brought to the attention of staff during circulation. Comprehensive education and training programmes exist including induction, mandatory training and modules as detailed in the Trust's education and training brochure. Specialist education will also be targeted at those with responsibility for managing the risk.

## 18.0 References and Associated Documentation

This policy was drafted with reference to the following:

British National Formulary (BNF)

Summary of Product Characteristics (SPC) of all medicines included. Available at: [medicines.org.uk](http://medicines.org.uk)

[NICE NG10 - Violence and aggression: short-term management in mental health, health and community settings. Published: 28 May 2015](#)

[NICE Quality Standard QS154 - Violent and aggressive behaviours in people with mental health problems. Published 29 June 2017](#)

Leicestershire Partnership Trust, Policy for Management of Violence & Aggression, Warning letters and Withholding treatment

[Violence and aggression: short-term management in mental health, health and community settings \(NG10\)](#)

## APPENDICES

**Appendix 1: Recording Sheet for IM Rapid Tranquillisation**  
(overleaf: page 22)

# Recording Sheet for IM Rapid Tranquillisation

All parts must be completed

**Patient Label**

[Write full name until label can be sought]

<b>Ward</b>		<b>MHA status</b>	
<b>Date</b>		<b>Time of injection</b>	
<b>Capacity to consent?</b>		<b>Consent to treatment in place?</b>	
<b>Staff administering injection: [Print names]</b>			
<b>Medication administered</b>		<b>Dose</b>	

A Nurse will ensure that the following duties are carried out	Time done
Allocate staff for observations duties	
Contact Ward/Duty Doctor to review patient	
Inform Doctor on arrival of if there are any concerns re: <ul style="list-style-type: none"> <li>• Medical conditions</li> <li>• Prolonged restraint</li> <li>• Patient has used illicit drugs/alcohol</li> </ul>	
Document in <b>electronic patient record</b> that: 1. Patient has been given RT 2. Their response to the medication 3. Their capacity related to this 4. Any concerns from observations taken after RT	
If RT already identified as an intervention in patient's <b>Care Plan</b> , evaluate the care plan with its use	
Update the patient's <b>Care Plan/Risk Assessment</b> with the use of RT as an intervention if not already identified as one	
Diarise <b>post RT incident review</b> for the following day	
Complete an Electronic Incident Reporting Form - <b>eIRF</b>	

Allocated Staff to document:	
All required physical observations by completing <b>NEWS2</b> form on <b>NerveCentre</b>	Side-effects & Level of hydration in patient's <b>electronic patient record</b>
To be done at least <b>hourly</b> , until there are no further concerns about patient's physical health status	
Or every <b>15 minutes</b> if the <b>BNF maximum dose</b> has been exceeded, or if the patient:	
<ul style="list-style-type: none"> <li>• appears to be asleep or sedated</li> <li>• has taken illicit drugs or alcohol</li> </ul>	<ul style="list-style-type: none"> <li>• has a pre-existing physical health problem</li> <li>• has experienced any harm as a result of any restrictive intervention</li> </ul>

If a patient **refuses** to have their **vital signs** measured: **Allocated Staff** to document in **electronic patient record** every **15 minutes** as a minimum:    • **AVPU**            and            • **Respiratory rate**

A = Alert/Awake      V = responds to Verbal stimuli      P = responds to Pain/Pressure stimuli      U = Unresponsive

Allocated Staff [Print names]	Hr.1	Hr.5	Hr.9

# Post rapid tranquillisation review for patients

**Patient Label**

[Write full name until label can be sought]

**What happened in the incident?**

**How do you feel about the incident**

**In your mind, what led to the incident?**

**What other coping strategies/distraction/calm down methods/activities could we have helped you engage in to prevent this in future?**

**How do you feel about the way staff involved you during the incident?  
Is there anything else they could have done differently?**

<b>Care plan reviewed?</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>	<b>If not completed, please explain why:</b>

<b>Risk Assessment updated?</b>	Yes <input type="checkbox"/>	No <input type="checkbox"/>	<b>If not completed, please explain why:</b>

<b>Date</b>		<b>Patient signature</b>	
-------------	--	--------------------------	--


<b>Staff name</b>		<b>Staff signature</b>	
-------------------	--	------------------------	--

<b>Charge Nurse/Sister Review</b>	<b>Date:</b>
-----------------------------------	--------------

<b>Name</b>	
-------------	--

<b>Signature</b>	
------------------	--

## Appendix 2: Quick Reference Guide to Rapid Tranquillisation (QRG)



## Appendix 3: Due Regard

\*A full Due Regard (Equality Analysis) makes sure that any negative impacts have been considered and ways to minimize the impact are specified.

### Due Regard Screening Template

Section 1		
Name of activity/proposal	RAPID TRANQUILLISATION Policy	
Date Screening commenced	March 2014	
Directorate / Service carrying out the assessment	Pharmacy Dept.	
Name and role of person undertaking this Due Regard (Equality Analysis)	Z Patel	
Give an overview of the aims, objectives and purpose of the proposal:		
<b>AIMS:</b>	This policy describes the appropriate use of RT injectable medication to control severe mental and behavioural disturbance, including aggression associated with mental illness.	
<b>OBJECTIVES:</b>	The <b>primary</b> objective in the use of these guidelines is to bring to an end a period of highly disturbed behaviour in a patient resistive to intervention as <b>quickly</b> and as <b>safely</b> as possible.	
<b>PURPOSE:</b>	The purpose of RT is to calm the person, and reduce the risk of violence and harm, rather than to treat the underlying psychiatric condition. An optimal response would be a reduction in agitation or aggression without sedation, allowing the patient to participate in further assessment and treatment.	
Section 2		
Protected Characteristic	Could the proposal have a positive impact Yes or No (give details)	Could the proposal have a negative impact Yes or No (give details)
Age	<p><b>Yes</b> - Prevents injury to individual and other service users (irrespective of any equality group) including carers/members of staff present, by controlling a period of highly disturbed behaviour.</p> <p>Information will be available in alternative formats such a relevant language, larger print or where applicable through interpretation and translation services</p>	<p><b>Yes</b> - A loss of control by individual or negative views of RT. This might in part be mitigated by use of behavioural approaches and de-escalation techniques, e.g. talking down, distraction, time out etc. Even when they do not prevent the need for RT, such actions will help preserve the therapeutic relationship and improve safety. Before administering any medication, the patient is informed that medication needs to be given and there is the opportunity to take the medication orally.</p>
Disability		
Gender reassignment		
Marriage & Civil Partnership		
Pregnancy & Maternity		
Race		
Religion and Belief		
Sex		
Sexual Orientation		
Other equality groups?		

<b>Section 3</b>			
<b>Does this activity propose major changes in terms of scale or significance for LPT? For example, is there a clear indication that, although the proposal is minor it is likely to have a major affect for people from an equality group/s? Please <u>tick</u> appropriate box below.</b>			
Yes		No ✓	
High risk: Complete a full EIA starting click <a href="#">here</a> to proceed to Part B		Low risk: Go to Section 4.	<input checked="" type="checkbox"/>

<b>Section 4</b>
<b>It this proposal is low risk please give evidence or justification for how you reached this decision:</b>
The requirement for consideration of use of RT medication pertains to a widespread group of individuals (any protected characteristic), and is a means of preventing further injury. It is undertaken in line with policy in order to ensure that actions are proportionate, within agreed parameters, ensuring dignity and respect is maintained and well documented.

*Sign off that this proposal is low risk and does not require a full Equality Analysis:*

**Head of Service Signed:** 

**Date:** 29/01/2020

**Lead Pharmacist Signed:** 

**Date:** 29/01/2020

## Appendix 4: Policy Training Requirements

The purpose of this template is to provide assurance that any training implications have been considered

<b>Training topic:</b>	
<b>Type of training:</b>	<input checked="" type="checkbox"/> Mandatory (must be on mandatory training register) <input checked="" type="checkbox"/> Role specific <input type="checkbox"/> Personal development
<b>Division(s) to which the training is applicable:</b>	<input checked="" type="checkbox"/> Adult Learning Disability Services <input checked="" type="checkbox"/> Adult Mental Health Services <input checked="" type="checkbox"/> Community Health Services <input type="checkbox"/> Enabling Services <input type="checkbox"/> Families Young People Children <input type="checkbox"/> Hosted Services
<b>Staff groups who require the training:</b>	<i>Please specify...</i>
<b>Update requirement:</b>	
<b>Who is responsible for delivery of this training?</b>	
<b>Have resources been identified?</b>	
<b>Has a training plan been agreed?</b>	
<b>Where will completion of this training be recorded?</b>	<input checked="" type="checkbox"/> Trust learning management system <input type="checkbox"/> Other (please specify)
<b>How is this training going to be monitored?</b>	

## Appendix 5: The NHS Constitution

### NHS Core Principles – Checklist

Please tick below those principles that apply to this policy

**The NHS will provide a universal service for all based on clinical need, not ability to pay. The NHS will provide a comprehensive range of services**

Shape its services around the needs and preferences of individual patients, their families and their carers	<input checked="" type="checkbox"/>
Respond to different needs of different sectors of the population	<input checked="" type="checkbox"/>
Work continuously to improve quality services and to minimise errors	<input checked="" type="checkbox"/>
Support and value its staff	<input checked="" type="checkbox"/>
Work together with others to ensure a seamless service for patients	<input type="checkbox"/>
Help keep people healthy and work to reduce health inequalities	<input type="checkbox"/>
Respect the confidentiality of individual patients and provide open access to information about services, treatment and performance	<input checked="" type="checkbox"/>

## Appendix 6: Privacy Impact Assessment Screening

Privacy impact assessment (PIAs) are a tool which can help organisations identify the most effective way to comply with their data protection obligations and meet individual's expectations of privacy. The first step in the PIA process is identifying the need for an assessment.

The following screening questions will help decide whether a PIA is necessary.

Answering 'yes' to any of these questions is an indication that a PIA would be a useful exercise and requires senior management support, at this stage the Head of Data Privacy must be involved.

<b>Name of Document:</b>	Rapid Tranquillisation Policy		
<b>Completed by:</b>	Zeibun Patel		
<b>Job title:</b>	Lead Pharmacist	<b>Date</b>	03/04/2018
			<b>Yes / No</b>
1. Will the process described in the document involve the collection of new information about individuals? This is information in excess of what is required to carry out the process described within the document.			No
2. Will the process described in the document compel individuals to provide information about themselves? This is information in excess of what is required to carry out the process described within the document.			No
3. Will information about individuals be disclosed to organisations or people who have not previously had routine access to the information as part of the process described in this document?			No
4. Are you using information about individuals for a purpose it is not currently used for, or in a way it is not currently used?			No
5. Does the process outlined in this document involve the use of new technology which might be perceived as being privacy intrusive? For example, the use of biometrics.			No
6. Will the process outlined in this document result in decisions being made or action taken against individuals in ways which can have a significant impact on them?			No
7. As part of the process outlined in this document, is the information about individuals of a kind particularly likely to raise privacy concerns or expectations? For examples, health records, criminal records or other information that people would consider to be particularly private.			No
8. Will the process require you to contact individuals in ways which they may find intrusive?			No
<p>If the answer to any of these questions is 'Yes' please contact the Head of Data Privacy Tel: 0116 2950997            Mobile: 07825 947786  <a href="mailto:Lpt-dataprivacy@leicspart.secure.nhs.uk">Lpt-dataprivacy@leicspart.secure.nhs.uk</a>            In this case, ratification of a procedural document will not take place until approved by the Head of Data Privacy.</p>			
<b>IG Manager approval name:</b>			
<b>Date of approval</b>			

Acknowledgement: Princess Alexandra Hospital NHS Trust